Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The value, qualification, and regulatory use of surrogate end points in drug development.
Lathia CD, Amakye D, Dai W, Girman C, Madani S, Mayne J, MacCarthy P, Pertel P, Seman L, Stoch A, Tarantino P, Webster C, Williams S, Wagner JA. Lathia CD, et al. Among authors: tarantino p. Clin Pharmacol Ther. 2009 Jul;86(1):32-43. doi: 10.1038/clpt.2009.69. Epub 2009 May 27. Clin Pharmacol Ther. 2009. PMID: 19474783 Review.
Antibody-drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis.
Michelon I, Dacoregio MI, Vilbert M, Priantti J, do Rego Castro CE, Vian L, Tarantino P, de Azambuja E, Cavalcante L. Michelon I, et al. Among authors: tarantino p. Ther Adv Med Oncol. 2024 Nov 20;16:17588359241297079. doi: 10.1177/17588359241297079. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39574495 Free PMC article.
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆.
Raghavendra AS, Zakon DB, Jin Q, Strahan A, Grimm M, Hughes ME, Cherian M, Vincuilla J, Parker T, Tarantino P, Mittendorf EA, King TA, Valero V, Tripathy D, Tolaney SM, Tayob N, Lin NU, Stover DG, Barcenas CH, Garrido-Castro AC. Raghavendra AS, et al. Among authors: tarantino p. ESMO Open. 2024 Nov;9(11):103973. doi: 10.1016/j.esmoop.2024.103973. Epub 2024 Nov 4. ESMO Open. 2024. PMID: 39500139 Free PMC article.
Progress in breast cancer management.
Tarantino P, Tolaney SM. Tarantino P, et al. Lancet. 2024 Oct 12;404(10461):1376-1378. doi: 10.1016/S0140-6736(24)01823-3. Lancet. 2024. PMID: 39396338 No abstract available.
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
Nader-Marta G, Singer C, Hlauschek D, DeMichele A, Tarantino P, de Azambuja E, Pfeiler G, Martin M, Balko JM, Nowecki Z, Balic M, Brufsky AM, Chan A, Morris PG, Haddad T, Loibl S, Liu Y, Soelkner L, Fesl C, Mayer EL, Gnant M; PALLAS groups and investigators. Nader-Marta G, et al. Among authors: tarantino p. Breast Cancer Res. 2024 Oct 7;26(1):140. doi: 10.1186/s13058-024-01899-2. Breast Cancer Res. 2024. PMID: 39375745 Free PMC article. Clinical Trial.
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.
Waks AG, Martínez-Sáez O, Tarantino P, Braso-Maristany F, Pascual T, Cortés J, Tolaney SM, Prat A. Waks AG, et al. Among authors: tarantino p. Nat Rev Clin Oncol. 2024 Nov;21(11):818-832. doi: 10.1038/s41571-024-00939-2. Epub 2024 Sep 13. Nat Rev Clin Oncol. 2024. PMID: 39271787 Review.
205 results